A Study of ONCO-DOX in Locally Advanced Hepatocellular Carcinoma

Summary

This is a prospective, multicenter study that will be conducted at up to 40 centers in the United States and Outside United States (OUS). Participants in the study will be randomly assigned to receive either ONCO-DOX or sorafenib treatment. This study will evaluate the study participants' outcomes (medical condition) after being treated with ONCO-DOX and compare it to those treated with sorafenib alone.

Timeline

Start

2015-11

Primary completion

2017-06-05

Completion

2017-06-05

Drugs

Indications